Patent US2196623A successfully refreshed from Google Patents.
Patent US5470734A successfully refreshed from Google Patents.
US5470734A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Recombinant herpesvirus of turkeys and live vector vaccines derived thereof
Assignee: Intervet International BV
•
Filing: 1993-02-16
•
Granted: 1995-11-28
•
Expires: 2013-02-16
Abstract
Abstract The present invention is concerned with a recombinant Herpesvirus of Turkeys (HVT), containing a heterologous gene incorporated into an insertion region of the genome of HVT. The invention also relates to a vector vaccine comprising such a recombinant HVT which expresses a heterologous antigenic polypeptide and induces an adequate immune response on infection of an appropriate host animal.
Inventors
- 👤 Paulus J. A. Sondermeijer
- 👤 Johannes A. J. Claessens
- 👤 Albert P. A. Mockett
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-08 23:23
CPC Classifications
C; C12; C12N; C12N7/00; C12N7/04; C12N15/00; C12N15/09; C12N15/63; C12N15/79; C12N15/85; C12N15/86; A; A61; A61P; A61P31/00; A61P31/12; C07; C07K; C07K14/00; C07K14/005; A61K; A61K39/00; C12N2710/00; C12N2710/00011; C12N2710/16011; C12N2710/16311; C12N2710/16322; C12N2710/16341; C12N2710/16343; Y; Y10; Y10S; Y10S424/00; Y10S424/816
Claims Analysis
Total Claims: 10
Claim 1
Independent Claim
62 words
A vaccine comprising a recombinant herpesvirus of turkeys (HVT) comprising a heterologous nucleic acid sequence that encodes an antigen of an avian pathogen, said nucleic acid sequence being introduced in an insertion region of the HVT genome from the end of ORF-1 through ORF-5 located within a DNA fragment of the HVT genome having a restriction enzyme map defined in FIG. 1.
Claim 2
Dependent Claim
62 words
A vaccine comprising a recombinant herpesvirus of turkeys (HVT) comprising a heterologous nucleic acid sequence that encodes an antigen of an avian pathogen, said nucleic acid sequence being introduced in an insertion region of the HVT genome from the end of ORF-1 through ORF-5 located within a DNA fragment of the HVT genome having a restriction enzyme map defined in FIG. 1.
Claim 3
Dependent Claim
50 words
A vaccine comprising a recombinant herpesvirus of turkeys (HVT) that contains a heterologous nucleic acid sequence that encodes an antigen of an avian pathogen, said nucleic acid sequence being introduced in an insertion region of the HVT genome between nucleotide positions 82 and 4504 as defined in SEQ ID NO:1.
Claim 4
Dependent Claim
50 words
A vaccine comprising a recombinant herpesvirus of turkeys (HVT) that contains a heterologous nucleic acid sequence that encodes an antigen of an avian pathogen, said nucleic acid sequence being introduced in an insertion region of the HVT genome between nucleotide positions 82 and 4504 as defined in SEQ ID NO:1.
Claim 5
Dependent Claim
16 words
The vaccine of claim 1, wherein the insertion region is in ORF-2, ORF-3, ORF-4 or ORF-5.
Claim 6
Dependent Claim
23 words
The vaccine of claim 3, wherein the heterologous nucleic acid sequence is inserted at the BgLII restriction site present in ORF-2 or ORF-3.
Claim 7
Dependent Claim
29 words
The vaccine of claim 2, wherein at least part of the HVT nucleic acid sequence of the ORF within which the heterologous nucleic acid sequence is introduced is deleted.
Claim 8
Dependent Claim
33 words
The vaccine of claim 1, wherein the heterologous nucleic acid sequence is under control of a promoter regulating the expression of said nucleic acid sequence in a cell infected with said recombinant HVT.
Claim 9
Dependent Claim
34 words
The vaccine of claim 1, wherein the antigen is an antigen selected from the group of avian pathogens consisting of Marek's Disease Virus, Infectious Bronchitis Virus, Newcastle's Disease Virus and Infectious Bursal Disease Virus.
Claim 10
Dependent Claim
34 words
The vaccine of claim 2, wherein the antigen is an antigen selected from the group of avian pathogens consisting of Marek's Disease Virus, Infectious Bronchitis Virus, Newcastle's Disease Virus and Infectious Bursal Disease Virus.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1998-11-27 | 1999-05-29 | 1999-11-28 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2002-11-27 | 2003-05-29 | 2003-11-28 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2006-11-27 | 2007-05-29 | 2007-11-28 | $7700.00 | Window Closed / Lapsed |